CTLA4 and hereditary clear cell renal cell carcinoma: Checkpoint inhibition therapies targeting PD-L1 or CTLA-4 pathways have shown promising effects in patients with renal cell carcinoma (Choueiri et al., 2016; Motzer et al., 2018).